ENSPRYNG (satralizumab)

Moderate-to-severe thyroid eye disease · Adults with moderate-to-severe active thyroid eye disease

RHHBY · Roche Holdings AG

Regulatory designations

Full timeline

4 milestones

FDA approved ENSPRYNG for thyroid eye disease

FDA approved ENSPRYNG for adults with thyroid eye disease, making it the first FDA-approved at-home subcutaneous treatment option for the condition.

Roche — ENSPRYNG FDA approval announcement↗

FDA decision expected

FDA assigned an October 15, 2026 PDUFA goal date to the ENSPRYNG supplemental BLA for thyroid eye disease.

Roche — Enspryng sBLA acceptance and PDUFA date↗

FDA accepted the sBLA with Priority Review

FDA accepted the ENSPRYNG supplemental BLA and granted Priority Review for the treatment of thyroid eye disease.

Roche — Enspryng sBLA acceptance and Priority Review↗

SatraGO Phase 3 data were presented

Roche presented Phase 3 SatraGO-1 and SatraGO-2 results showing improvements across key thyroid eye disease endpoints, including proptosis and diplopia.

Roche — SatraGO programme data and regulatory update↗

Related News

Information for research purposes only · Dates can change · Last updated Oct 30, 2026